NCT04006652View on ClinicalTrials.gov

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
Acute Graft Versus Host DiseaseHaploidentical Hematopoietic Stem Cell Transplant
Interventions
DRUG

ApoGraft

ApoGraft is a cell based product, manufactured with mobilized peripheral blood.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Cellect Biotechnology
All Listed Sponsors
collaborator

Cellect Biotechnology

INDUSTRY

lead

Washington University School of Medicine

OTHER